Printer Friendly

VaxyGen, GSURF sign exclusive licence, collaboration deal.

M2 PHARMA-October 20, 2011-VaxyGen, GSURF sign exclusive licence, collaboration deal(C)2011 M2 COMMUNICATIONS

20 October 2011 - US VaxyGen Manufacturing Services LLC, a unit of VaxyGen Holdings LLC, said it had signed an exclusive licence and collaboration agreement with Georgia State University Research Foundation (GSURF).

The agreement provides VaxyGen with a licence to a patent for producing and purifying proteins in development as biopharmaceutical products and vaccines.

Under the collaborative contract, VaxyGen will be responsible for marketing the expertise and know-how resident in the Georgia State University Biological Process Development and Research Laboratory.

VaxyGen Manufacturing Services offers custom contract services in support of biological process optimisation, scale-up and the development of manufacturing processes relative to biopharmaceutical and vaccine products.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 20, 2011
Words:130
Previous Article:Actelion net profit declines to CHF81.6m in Q3 2011.
Next Article:Lilly's Q3 2011 net income slightly declines.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters